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General Reagents 
Unless otherwise noted, reagents were purchased from the commercial suppliers Fisher 
(Fairlawn, NJ) and Sigma-Aldrich (St. Louis, MO) and were used without further purification. 
 
General Methods 
Preparation of cultured neuronal and brain lysates.  Cultured cortical neurons and dissected 
brain cortices were lysed and separated into nuclear and S100 fractions as described previously1, 
except for the following modifications.  For the kainic acid samples, crude nuclear pellets were 
washed (with homogenization buffer not containing PUGNAc or GlcNAc) and lysed directly into 
boiling 1% SDS by sonication for 3 x 3 sec.  After centrifugation at 21,500 xg for 5 min, the 
supernatant was collected as denatured nuclear extract.  Prior to labeling, non-denatured nuclear 
and cytoplasmic extracts were dialyzed into 20 mM HEPES pH 7.9, 0.1 M KCl, 0.2 mM EDTA, 
0.2% Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride (PMSF).  Prior to labeling, denatured 
nuclear extracts were diluted 5-fold with 100 mM HEPES pH 7.9, 5 M NaCl and 20% Triton-
X100 to a final concentration of 10 mM HEPES pH 7.9, 100 mM NaCl and 1.8% Triton-X100.  
Western blots of the kainic acid samples were performed on rat cortices lysed directly into boiling 
1% SDS by sonication for 9 x 5 sec.  After centrifugation at 21,500 xg for 5 min, the supernatant 
was collected as denatured cellular extract. 
 
Chemoenzymatic labeling of cultured neuronal and brain lysates.  α-Crystallin (6.5-11 µg, ~ 
1:1 mixture of A and B crystallin, Sigma) was denatured by boiling for 5 min in 1% SDS 
containing 25 mM DTT and added to extracts prior to labeling.  Similarly, OGT (0.8-2 µg in 50 
mM Na2HPO4 pH 7.5, 1 mM DTT, 20% glycerol) purified from Sf9 cells2 was denatured by 
boiling for 5 min in 1% SDS containing 25 mM DTT and added to the extracts.  These quantities 
represent levels of α-crystallin and OGT that are several-fold higher than the endogenous levels.  
Extracts (0.5-3 mg; 1-3 mg ml-1) containing the α-crystallin and OGT standards were 
supplemented with 5 mM MnCl2, 1 mM PMSF and Complete™ protease inhibitor tablets 
(Roche).  The extracts were then incubated with the UDP-ketogalactose probe (1, 0.5 mM) and 
mutant Y289L GalT enzyme (60 ng µl-1) for 12-14 h at 4 °C.  1 was synthesized and the mutant 
GalT was expressed and purified essentially as described3.  Following enzymatic labeling, 
extracts were dialyzed into denaturing buffer (5 M urea, 10 mM HEPES pH 7.5; 3 x 3 h).  The pH 
was adjusted with 2.7 M NaOAc pH 3.9 (final concentration 50 mM, pH 4.8), N-
(aminooxyacetyl)-N'-(D-biotinoyl) hydrazine (30 mM aqueous stock, Dojindo) was added to a 
final concentration of 2.75 mM, and the reactions were incubated for 20-24 h at room 
temperature.  Extracts were dialyzed (2 x 2 h, 1 x 10 h) into 7 M urea, 10 mM HEPES pH 7.5 at 
room temperature, followed by 2 M urea, 50 mM NH4HCO3 pH 8 (3 x 3 h) at 4 ºC.  
 
Proteolytic digestion.  Dialyzed extracts were reduced in 10 mM DTT for 1 h at room 
temperature, alkylated in 20 mM iodoacetamide for 1 h at room temperature, and incubated with 
20 mM DTT for 1 h at room temperature to react with excess iodoacetamide.  The extract 
solution was then centrifuged at 15,000 rpm for 5 min to remove any insoluble material.  Control 
and experimental extracts were adjusted to identical protein concentrations with excess 2 M urea, 
50 mM NH4HCO3 pH 8 and then diluted with 50 mM NH4HCO3 pH 8 to a final urea 
concentration of 1 M.  Sequencing-grade trypsin (Promega) was added to provide a final extract 
to trypsin ratio of 20:1.  The trypsin concentration was always maintained above 0.01 mg ml-1, 
and digestion was carried out in a water bath at 37 ºC for 12-14 h. 
 
LC-MS analysis.  Approximately 1/5 of the avidin-enriched peptides from each cation exchange 
fraction was loaded onto a 360 µm O.D. X 75 µm I.D. precolumn packed with 4 cm of 5 µm 
Monitor C18 particles (Column Engineering) at a flow rate of 4 µl min-1.  After desalting, the 
vent was closed and peptides eluted to a 360 µm O.D. X 75 µm I.D. analytical column with 
integrated emitter tip (10 cm of 5 µm C18, ca. 5 µm tip).  The chromatographic profile was from 
100% solvent A (0.1% aqueous AcOH) to 50% solvent B (0.1% AcOH in CH3CN) in 30 min.  
The flow rate through the analytical column was approximately 100 nl min-1.   
 
Chemoenzymatic labeling and streptavidin capture of O-GlcNAc proteins.  Chemoenzymatic 
labeling was performed on neuronal lysates as described above.  After reaction with the 
aminooxy biotin derivative, proteins were dialyzed (1 x 10 h, 2 x 3 h) into 7 M urea, 10 mM 
HEPES, pH 7.5 at room temperature followed by 10 mM HEPES pH 7.5, 100 mM NaCl, 0.2% 
Triton-X 100 (2 x 2 h, 1 x 10 h) at 4 °C.  Fresh PMSF (1 mM) was added at each stage of 
dialysis.  Proteins were captured on streptavidin beads as previously described4 and probed by 
immunoblotting. 
 
Western blotting.  Lysates were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes and immunoblotted as described previously4.  Total O-GlcNAc levels were monitored 
using the anti-O-GlcNAc antibody CTD110.6 (Covance, 1:5000).  The following primary 
antibodies were also used: EGR-1 (Upstate Biotechnology, 1:1000), GRASP-55 (BD 
Transduction Laboratories, 1:1000), eIF4G (Santa Cruz, 1:100), OGA (a kind gift from Prof. 
Sidney Whiteheart, University of Kentucky, 1:1000), p66β (Upstate, 1:500) and SRC-1 (Santa 
Cruz, 1:100).  After incubation with the secondary antibodies IRDye 800 goat anti-rabbit 
(Rockland Immunochemicals) or Alexa Fluor 680 goat anti-mouse (Molecular Probes), proteins 
were visualized and quantified using the Odyssey infrared imaging system (LI-COR 
Biosciences).  To quantify differences in O-GlcNAc levels, we measured the relative intensities 
of the input bands (lysate prior to streptavidin capture) and eluent bands (lysate after streptavidin 
capture) using Odyssey imaging software (Version 2.1).  For each sample, the ratio of the eluent 
signal to the corresponding signal was calculated.  The resulting values were corrected for non-
specific background by subtracting the corresponding ratios from control reactions performed in 
the absence of GalT.  The corrected intensity for the PUGNAc-treated sample was then divided 
by the corrected intensity for the untreated sample to determine the fold increase.  In Figure 5b, 
the fold-change for the untreated sample was normalized to 1.0 for each protein.  
 
Statistical analysis.  Quantification was conducted by generating single ion chromatograms from 
the orbitrap MS scans for candidate O-GlcNAc peptides.  Peak areas of isotopic clusters were 
derived using Xcalibur 1.4 software.  Mean values, standard deviations and confidence intervals 
were calculated using the program Excel on log-transformed ratios and reported in the original 
scale as previously described5,6.  We used the geometric standard deviation (g.s.d.) to calculate 
maximum absolute standard deviations and reported these values in Supplementary Tables 1 and 
2.  Standard peptide ratios were tested for goodness of fit to the log-normal distribution via the 
D’Agostino-Pearson omnibus test and were used to determine the confidence with which changes 
in experimental peptides could be detected.  Experimental peptide ratios were normalized against 
the slope of the linear regression produced by the heavy versus light forms of standard peptides 
within experiments.   
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